The goal of the SFI is to provide non-invasive information about tissue remodeling
occurring during melanocytic transition and atypia development in the skin
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT03535077.
The goal of the SFI is to provide non-invasive information about tissue remodeling
occurring during melanocytic transition and atypia development in the skin. SFI analyzes
the topical staining of the skin surface using the ORL-1 dye to reveal the presence of
remodeling in the skin, together with the visible feature characteristics. The system
provides a biometric score corresponding to the dye staining, a structural score, and a
composite SFI score to quantify the presence of tissue remodeling and the process of
melanocytic transition in the skin.
Trial PhaseNo phase specified
Trial TypeNot provided by clinicaltrials.gov
Lead OrganizationOrlucent, Inc